

Claims:

1.     **(Original)**     A method for treating a disorder in which TNF $\alpha$  activity is detrimental comprising administering to a subject an effective amount of a TNF $\alpha$  inhibitor in a low dose therapy, such that the disorder is treated.
2.     **(Original)**     The method of claim 1, wherein the disorder is arthritis.
3.     **(Original)**     The method of claim 2, wherein the disorder is rheumatoid arthritis.
4.     **(Original)**     The method of claims 2 and 3, wherein symptoms selected from the group consisting of bone erosion, cartilage erosion, inflammation, and vascularity, are treated.
5.     **(Original)**     The method of claims 1-4, wherein the TNF $\alpha$  inhibitor is D2E7.
6.     **(Original)**     The method of claims 1-4, wherein the TNF $\alpha$  inhibitor is Etanercept or Remicade.
7.     **(Original)**     The method of claims 1-6, wherein the TNF $\alpha$  inhibitor is administered in a low dose comprising 0.01 - 2.0 mg/kg.
8.     **(Original)**     A method to alleviate symptoms associated with a disorder in which TNF $\alpha$  activity is detrimental, comprising administering a low dose of a TNF $\alpha$  inhibitor to a subject suffering from said disorder, such that the symptoms are treated.
9.     **(Original)**     The method of claim 8, wherein the disorder is arthritis.
10.    **(Original)**     The method of claim 9, wherein the disorder is rheumatoid arthritis.
11.    **(Original)**     The method of claims 9 and 10, wherein symptoms are selected from the group consisting of bone erosion, cartilage erosion, inflammation, and vascularity.

12.    **(Original)**    The method of claims 8-11, wherein the TNF $\alpha$  inhibitor is D2E7.
13.    **(Original)**    The method of claims 8-11, wherein the TNF $\alpha$  inhibitor is Etanercept or Remicade.
14.    **(Original)**    The method of claims 8-13, wherein the TNF $\alpha$  inhibitor is administered in a low dose comprising 0.01 - 2.0 mg/kg.
15.    **(Original)**    A method for treating arthritis comprising administering to a subject an effective amount of a TNF $\alpha$  inhibitor in a low dose therapy, such that the arthritis is treated.
16.    **(Original)**    The method of claim 15, wherein the arthritis is rheumatoid arthritis.
17.    **(Original)**    The method of claims 15 and 16, wherein arthritis is treated by alleviating symptoms selected from the group consisting of bone erosion, cartilage erosion, inflammation, and vascularity.
18.    **(Original)**    The method of claims 14-17 wherein the TNF $\alpha$  inhibitor is D2E7.
19.    **(Original)**    The method of claims 14-17, wherein the TNF $\alpha$  inhibitor is Etanercept or Remicade.
20.    **(Original)**    The method of claims 15-19, wherein the TNF $\alpha$  inhibitor is administered at a low dose comprising 0.01 - 2.0 mg/kg.
21.    **(Original)**    A method for treating symptoms associated with arthritis comprising administering to a subject a low dose of an effective amount of a TNF $\alpha$  inhibitor, such that the symptoms are alleviated.
22.    **(Original)**    The method of claim 21, wherein the arthritis is rheumatoid arthritis.

23. **(Original)** The method of claims 21 and 22, wherein the symptoms are selected from the group consisting of bone erosion, cartilage erosion, inflammation, and vascularity.
24. **(Original)** The method of claim 23, wherein the symptoms are further selected from the group consisting of joint distortion, swelling, joint deformation, ankylosis on flexion, and severely impaired movement.
25. **(Original)** The method of claims 21-24, wherein the TNF $\alpha$  inhibitor is D2E7.
26. **(Original)** The method of claims 21-24, wherein the TNF $\alpha$  inhibitor is Etanercept or Remicade.
27. **(Original)** The method of claims 21-26, wherein the TNF $\alpha$  inhibitor is administered at a low dose comprising 0.01 - 2.0 mg/kg.
28. **(Original)** A method of sequestering TNF $\alpha$  into complexes in a subject suffering from a disorder in which TNF $\alpha$  activity is detrimental, by administering a low dose of a TNF $\alpha$  inhibitor to the subject.
29. **(Original)** The method of claim 28, wherein the serum level of TNF $\alpha$  is higher than the serum level of TNF $\alpha$  in a subject not suffering from a disorder in which TNF $\alpha$  activity is detrimental.
30. **(Original)** The method of claims 28-29, wherein the TNF $\alpha$  inhibitor is D2E7.
31. **(Original)** The method of claims 1-30, wherein the TNF $\alpha$  inhibitor is administered with an additional therapeutic agent.

Restriction Under 35 U.S.C. 121

The Examiner has required restriction to one of the following inventions as required under 35 U.S.C. 121:

I. Claims 1-31, drawn to a method of treating a disorder with an anti-TNF $\alpha$  antibody; and

II. Claims 1-4, 6-11, 13-17, 19-24, 26-29 and 31, drawn to a method of treating a disorder with Etanercept.

Applicants hereby elect the Group I invention (claims 1-31) without traverse.

The Examiner has required that Applicants elect a species wherein the disorder is selected from the following:

- a. sepsis;
- b. autoimmune disease;
- c. infectious disease;
- d. transplantation;
- e. malignancy;
- f. pulmonary disorder;
- g. intestinal disorder;
- h. cardiac disorder;
- i. neurological disorder;
- j. metabolic disorder;
- k. liver disease;
- l. inflammatory disease;
- m. degenerative bone and joint disease,
- n. reperfusion injury; or
- o. other conditions described in the specification.

Applicants hereby elect the species autoimmune disorders without traverse.

The Examiner has also requested that Applicants elect "a specific species disclosed in the specification...as it reads on the elected species." Applicants elect the specific species of rheumatoid arthritis without traverse.


-6-

With respect to the elected species, it is Applicants understanding that the election of a species and specific species is for searching purposes only. It is also Applicants understanding that upon allowance of the elected claims, the generic claims also will be searched and Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. Applicants hereby reserve the right to traverse the species and specific species elections if Applicants' understanding is incorrect.

In addition, the Examiner has required that Applicants point out which claims are readable for the elected species. Applicants submit that claims 1-31 are readable for the elected species of autoimmune disorders.

If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' attorney at (617) 227-7400.

Respectfully submitted,



---

Elizabeth A. Hanley, Esq.  
Registration No. 39,505  
Attorney for Applicants

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, MA 02109  
Tel. (617) 227-7400  
Dated: November 12, 2004